On September 3, in the exhibition area of the 2021 Service and Trade Fair, the new crown special drug launched by the Sinopharm Group attracted much attention.
According to reports, this special immunoglobulin for the treatment of new coronary pneumonia has been put into clinical emergency treatment.
The specific immunoglobulin is prepared from plasma containing high titer neocorona antibody as raw material, and contains high titer SARS-CoV-2 neutralizing antibody.
The intravenous COVID-19 human immunoglobulin (pH4) developed by Sinopharm Wuhan Blood Products Co., Ltd. is a new class of therapeutic biological products and the world's first new coronary pneumonia-specific treatment drug prepared from plasma after immunization with a new coronary inactivated vaccine. , Has obtained clinical trial approvals in China and the UAE.
(Reporter Liu Chao Shan Lu produces Zhou Jing)
Editor in charge: [Zhang Aolin]